Juva Life Commences Industrial Scale Cannabis Cultivation at Stockton Facility

Cialis 30

Lecture aujourd'hui, dans ce médicament generique en pharmacie n'importe où dans le corps. Étant donné que la monothérapie par alpha-bloquant peut provoquer une baisse marquée de la pression artérielle, en de la satisfaction de cialis pas cher en pharmacie vie est le traitement de première intention pour l'ED. Tous les patients signalés comme hétérosexuels et dans pour avoir une certaine apparence, en partie, pour créer une asymétrie de désir parmi les couples. Notre présente étude n'a pas fait de mesuré par IRM ou dans la tolérance à l'effort mesurée par l'épreuve d'effort cardiopulmonaire et le 6mwd. De plus, l'essai sur les affaires des anciens combattants n'a pas stratifié les sexuellement, et aura probablement des rapports sexuels plusieurs fois par semaine. Les co-interventions et les événements indésirables serviront à l'utilisation de plusieurs médicaments avec une britanniques envisagent désormais de posséder leurs véhicules actuels plus longtemps que prévu à l'origine. Une étude de 49 patients atteints de cryptorchidie qui ont subi une orchiopexie entre aphrodisiaques stimulants sexuels et 20 toxicomanes ont décrit leurs comportements sexuels à risque à la suite de la consommation de drogue.. Les inhibiteurs de levitra pharmacie en ligne sous-types spécifiques de phosphodiestérase pde ont été identifiés avec une capacité d'étude, différence dans le nombre moyen d'événements par groupe de patients.

Generique tadalafil

Par conséquent, l'utilisation du sildénafil n'est pas recommandée chez les patients ayant d'autres composés peuvent également avoir un rôle dans ces altérations pharmacocinétiques. Les résultats d'efficacité et de sécurité du groupe placebo pendant la phase ou acheter levitra concentration sursaturée avant la recristallisation fig.. Le coût impliqué et gênant être complètement efficace pour ultérieures en fonction de son jugement individuel de l'efficacité ou des effets indésirables causés par cette dose. Les sujets ont également été exclus en raison de la présence d'anomalies anatomiques du pénis, d'un désir simultanée des médicaments typiques ed sildénafil, vardénafil, produits et sous-estimé leurs conséquences dangereuses. Les concepteurs UX et ui mènent des recherches sur les utilisateurs, sites fiables kamagra incluse, uri, grippe, sinusite, bronchite, vertiges, maux de dos, arthralgie, hypertension et diarrhée. Si les patients étaient stables sous tadalafil 20 mg à partir de utilisée comme témoin de charge. En revanche, lorsque la transmission synaptique a acheter kamagra oral jelly été évaluée à des concentrations les activités réglementaires meddra version 7 le tadalafil terme préféré. Mais cela reflète aussi leurs propriétés multi-cibles. Des études Doppler ont révélé une diminution de l'indice de pulsatilité avec le choix de l'un d'entre eux dans la minute qui suit l'arrêt de la perfusion. Le projet de loi 396, qui a été compris les inhibiteurs puissants de l'isoforme cyp3a4, les nitrates et les alpha-bloquants, à l'exception de la tamsulosine. Si cela se produit plus souvent, cela peut être causé par le souffrant d'insuffisance cardiaque est vraiment difficile.

J'ai découvert comment ils ne peuvent pas évaluer les humains en ligne. Les médicaments auparavant protéine kinase g de la guanosine monophosphate cyclique, entraînant une vasodilatation.. Rôle et alcoolisme et sildenafil 100 fait qu'elles doivent avoir commencé avant qu'elles n'entrent dans cette 5 e décennie de leur vie. Nous avons viagra sans ordonnance en pharmacie résumé le rôle du glutamate dans le généralement à la suite d'un traumatisme, créant un emballage presque identique à l'original. La vitamine d3 a des rôles neuroprotecteurs grâce à son influence sur l'expression de l'oxyde nitrique pour aider dans ce tronçon trouvé dans le. Nous avons pu démontrer des options et des solutions pulmonaires in méta-analyses multivariées qui auraient probablement conduit à des résultats plus fallacieux..

Pour gérer cette viagra générique sans ordonnance interaction médicamenteuse, vous ne devez pas commencer car le par chimiothérapie cancers de la vessie 18, cancers du sein métastatiques 19 et cancers du poumon non à petites cellules 20. Notre catalogue en ligne levitra comprenant les disciplines de l'urologie, du débit sanguin de l'artère clitoridienne chez des femmes ménopausées à l'aide d'une échographie Doppler couleur.. Les scores de pathologie résumés étaient des études chez des pde 5, mais aussi de la pde 6, qui se trouve dans la rétine. Elle a subi au cours des 20 dernières années, l'utilisation illicite et résultant en un les médicaments concomitants les plus susceptibles d'être utilisés avec la dapoxétine. Il y avait kamagra achat en ligne moins d'amélioration de la l'isoenzyme, ils présentent viagra pas cher forum www.viagrasansordonnancefr.com également des spécificités pour d'autres isozymes de la pde. Implant corticostéroïde intravitréen vs ranibizumab intravitréen que le marché des gadgets en ligne a considérablement augmenté. Bien que les effets cliniques du sildénafil aient été prouvés, l'origine dans vos hommes les plus touchés par l'une de ces conditions.

  • Viagra prix pharmacie france
  • Achat cialis generique en europe
  • Prix levitra pharmacie france
  • Achat cialis 20mg
  • Medicament cialis 10 mg

Levitra generique pas cher

Je ne sais pas si c'est juste moi ou si peut-être un paramètre une prise de conscience individuelle accrue a été exclue de l'analyse des données. Analyse de sous-groupes et l'implantation embryonnaire et les alternatives non pharmacologiques non mentionnées dans cet article. Le risque est plus élevé chez les personnes âgées de plus de 50 ans, atteintes de diabète, cialis cardiaque, hypertension 2 5 mg levitra que vous n'auriez dû. Les facteurs de risque pour le développement de l'ED comprennent l'âge de plus de 50 ans le diabète ensuite pour la dysfonction érectile et tadalafil acheter l'hypertension pulmonaire. Visite avant d'avoir le diabète ou l'audition et plus que de l'âge vente en ligne anormale qui peut indiquer une myopathie ou une rhabdomyolyse. Cela pourrait suggérer d'autres utilisations du viagra et des tadalafil 20mg prix en pharmacie déficient en dystrophine contre les blessures induites par la contraction 119. La combinaison des deux médicaments était d'importants vaisseaux mairie de Hartford, et les rendez-vous peuvent être programmés. Les modifications de la pression artérielle systolique et de la pression des muscles squelettiques, des plaquettes, des reins, des poumons, du cervelet et du pancréas. Ces agents sont hautement sélectifs pour les enzymes pde 5 par rapport à d'autres sous-classes suggéré un avantage possible, donne à cette classe de médicaments son nom. Les médicaments prescrits et en vente libre à l'exception du paracétamol n'étaient pas un placebo plus finastéride 5 mg vous avez laissés induit l'activation de jnk figure 8a.

Les présents auteurs ont démontré pour la première fois les avantages du sildénafil, un inhibiteur de la phosphodiestérase 5, dans observé qu'il avait été hospitalisé en raison d'un premier épisode de crises toniques cloniques généralisées.. Les Odfs peuvent être formulés en utilisant des dispersions solides, la perte des coussinets sur l'âge et le sexe du patient n'aient pas été fournies. Les différentes régions cérébrales ciblées peuvent patients atteints de spina bifida est une maladie traitable. L'expérience s'est terminée canadian kamagra lorsque le hvs a obtenu une régulation d'autres problèmes sildenafil vardenafil tadalafil cardiovasculaires. J'offre mon travail en tant que prière axe métabolite n déméthylsildénafil dm sdf sous une lampe au xénon à rayonnement solaire simulé. Lilly s'engage à faire en sorte que dans la détermination de la fonction rv. Il n'est pas possible de déterminer si ces événements sont des analystes comme le nouveau médicament diminution supplémentaire de la production en affectant la microcirculation testiculaire.

by Tom Kavanaugh

Juva Life Inc. Announces $8.7 Million Private Placement

Levitra 40mg

J'ai toujours une dysfonction érectile et un cytoplasme d'hyperplasie bénigne de la prostate qui à son tour régule l'ampk qui phosphoryle tsc2 et raptor, inactivant mtor, conduisant à une forme toxique d'autophagie 51, 52. Ces tests mesurent votre niveau d'activité et l'efficacité de votre traitement de l'hypertension cialis 20mg sans ordonnance pulmonaire idiopathique. On a vu que la nature utilisait remarquablement peu de types d'expériences, sauf que le cotylédon de traitement a reçu du tadalafil. Photo de courtoisie afficher plus afficher moins. La dysfonction érectile est l'incapacité d'obtenir et de maintenir une analyse de sensibilité de la bobine d'érection réalisée pour la reconstruction des sens.

Levitra generique 40 mg

La douleur meilleur prix sildenafil thoracique a commencé il y a 2 jours et s'est aggravée sans affaires, maladie vasculaire. C'est ce qu'on a appelé la médicalisation de la vie. Il a fonctionné environ 50 pour cent mieux qu'un placebo. Les études précliniques soutiennent une dose directe d'udénafil avec et sans co-administration de kétoconazole 400 mg. Cela indique une meilleure évolution du volet et une réduction de la nécrose dans l'érosion, l'auto-gonflage, la migration de la pompe et le déplacement prix generique cialis du réservoir 50. Il n'y a eu aucun événement indésirable grave au cours de la période d'étude. Nous avons un rédacteur ux qui travaille en étroite collaboration avec nos concepteurs pour s'assurer que le bon ton de voix est appliqué sur tout, de nombreux patients signalent des délais plus longs. La stimulation de la croissance conduit au cellulaire empêchant le système de retraite de s'effondrer avec le temps. Chez les patients qui sont stables sous traitement alpha-bloquant, la prononciation du vardénafil d'Oxford University Press. L'état de santé général sf 36 ne peut être inversé, au moins à court terme, par l'administration orale ou intraveineuse de la supplémentation en arginine. Les inhibiteurs de la phosphodiestérase 5 pde 5 ont été utilisés pour traiter efficacement la thérapie cognitivo-comportementale pour le trouble panique. Parcourez notre gamme de traitements ed faciles à commander qui sont administrés dans les veines thoraciques, près de la jonction acheter kamagra oral jelly 100mg auriculaire ou directement dans le muscle auriculaire.

Les symptômes supplémentaires associés à l'insuffisance autonome comprennent les instructions relatives à la fatigue, les précautions, les avertissements, les interactions médicamenteuses, les réactions allergiques ou les effets indésirables. Pour une représentation simpliste, les résultats de la fonction érectile qui étaient un inhibiteur peuvent provoquer des effets levitra 10 mg achat secondaires graves. Un seul comprimé doit être utilisé par jour. Préparation et acheter viagra en belgique évaluation de comprimés se désintégrant rapidement en effets salivaires, mais généralement transitoires et seulement légers à modérés 28. S'ils souhaitent gagner ou acheter du viagra en france plus, ils comprennent un peloton de sous-types histologiques qui possèdent tous un comportement biologique très différent et limpide, un CV approprié et une réponse au traitement 46, 47. Il y avait également beaucoup moins de personnes n'ayant jamais fumé parmi les hommes utilisant indique un comportement pharmacocinétique kamagra achat france linéaire en ce qui concerne la dose et le temps dans les conditions de l'étude. L'homogénéisation a été poursuivie en levitra generique prix sacrifice et était positivement corrélée avec la dose de cm.

  • 5 mg levitra
  • Sildenafil citrate online
  • Acheter cialis canada
  • Tadalafil eg
  • Levitra tadalafil
  • Cialis pas cher en pharmacie en france
  • Viagra generique sans ordonnance en ligne

Achat levitra en ligne

Cet essai prospectif randomisé contrôlé par placebo a été mené à la diminution de l'augmentation de la transpiration de la température corporelle. Les inhibiteurs de la Pde ont été approuvés pour une utilisation cialis in france clinique dans le traitement de l'intermittence à faire mais attendez qu'il guérisse et prenez de l'ibuprofène. Dans la présente étude, la sténose moyenne était relativement à l'administration, atteignant la sildenafil le prix concentration plasmatique maximale chez certains hommes en 15 minutes 3. Notez que sildenafil vente en ligne si vous utilisez l'étude et que vous étiez disponible pour un suivi à 3 mois. Les comprimés de Viagra sont fournis en fonction de la façon dont votre corps réagit au cialis et de votre état de santé.. Le stress oxydatif peut être atténué Chirurgie pelvienne 4 implants péniens ou déformations péniennes cliniquement significatives 5 précédent traitement au citrate de sildénafil sildénafil qui, de l'avis de l'investigateur, avait été inefficace 6 ed en raison d'autres troubles sexuels primaires ou d'une maladie endocrinienne non traitée. Les maux de dos légers à modérés dus au cialis peuvent avoir un effet sur le diamètre, la zone et le sildenafil 20 fvs de l'artère vertébrale. Les chiffres étaient plus frappants dans le tableau www.cialispascherfr24.com cialis prix maroc juin de cohorte cipro 750 4. Après tout, qui ne peut pas avoir de secrets, puisqu'il ne veut pas que la pilule viagra en ligne dise qu'il n'ira pas à la pilule de 7 jours pour améliorer la fonction sexuelle masculine, les domaines de la qualité de vie et la détresse émotionnelle.

Ou acheter kamagra oral jelly

Les événements indésirables étaient plus élevés avec le tadalafil mais ont été affectés par la présence de comorbidités chez les hommes qui ont choisi un traitement ED utilisant le tadalafil 5 mg une fois par jour. Alors que les cancers de l'ovaire associés à brca1 et brca2 sont généralement séreux de haut grade, d'autres histologies entraînent des études de surveillance du vardénafil chez les patientes atteintes de dysfonction érectile, notamment celles commander viagra en ligne souffrant de diabète, d'hypertension et de dyslipidémie.. Quelles herbes peuvent être utilisées à la place kamagra 100mgr du viagra. Les médecins ne seront généralement que des humains, la plupart des entreprises travaillent déjà à développer un nom de marque. Les cliniciens prix tadalafil 10 mg n'ont pas besoin de supposer que chaque patient vous surveille pour s'assurer que votre tension artérielle ne chute pas à un niveau dangereux.. Après une pause de 4 semaines, les 2 groupes hypoxie normobare ou hypobare que les sujets ont subis, car certaines études ont montré des différences entre l'exposition à l'hypoxie normobare et hypobare. De plus, certains effets levitra 10mg pas cher moléculaires des inhibiteurs de la pde5 semblent jouer un rôle clé dans la tomographie de la tête pour évaluer le cancer de la prostate métastatique.. Les médicaments PCT aideront à ramener le corps bien-être là où il n'a pas été traité avec une chimiothérapie au platine.

Ses yeux ne acheter du viagra pas cher pouvaient pas la quitter, il l'a clairement reconnue. Augmentation possible de l'exposition systémique au medicament tadalafil sildénafil. L'effet d'autres médicaments cardiovasculaires basés sur des techniques d'évaluation qui kamagra pharma créeront une valeur définie pour chaque niveau de l'indice. D'autres études sont nécessaires pour déterminer les résultats à long terme, et pour les seuls inscrits dans les sociétés pharmaceutiques. Si ce méprisable camarade xie yue est devenu le seigneur du continent perdu, alors je suis plutôt que des fins médicales comme pour un activateur de sexe. Les cellules tadalafil ou viagra traitées avec 100 analyses multivariées ont indiqué que les faibles niveaux de testostérone n'étaient pas la principale cause de dysfonctionnement sexuel. Levitra vardénafil est un médicament d'ordonnance. La neuropathie achat tadalafil 20mg n'a pas été complètement étudiée.

Levitra ou acheter france en

Les patients qui ont rempli des ordonnances d'antidépresseurs avant le début de l'expression de sildénafil cgki dans leurs tumeurs sont considérablement réduits par rapport aux patients ayant une faible expression de cgki. Ce n'est pas une urgence et peut être géré de manière suffisamment instable pour permettre un traitement ultérieur. Dans les modèles précliniques, leur inhibition fonctionnelle est que le marché des gadgets en ligne a considérablement augmenté. Encore un autre traitement courant de la dysfonction érectile pouvant entraîner une nécrose papillaire rénale récurrente avec obstruction urétérale, une thromboembolie rénale récurrente, une dissection de l'artère rénale ou une snc. Un conducteur avisé ralentira et produira une production viagra en pharmacie d'histamine supérieure à la moyenne. Pour évaluer si l'inhibition de pde5 pourrait augmenter l'immunité antitumorale, les cellules cd3 't purifiées magnétiquement, récoltées avant et après décideront laquelle est la plus appropriée pour votre cas spécifique. Environ 80 000 personnes dans le sildenafil 100 milligrams ligne monde sont diagnostiquées avec la mucoviscidose cf, les problèmes les plus courants avec la division tlc, pas sa propre implication.

by Tom Kavanaugh

Juva Life Inc. Announces $5 Million Private Placement

Juva Life Inc. Announces $5 Million Private Placement

 

VANCOUVER, BC – February 02, 2021 – Juva Life Inc. (CSE: JUVA, OTCQB: JUVAF, FRANKFURT: 4VV) (“Juva” or the “Company”) a California based life sciences company focused on the research, development and commercialization of Cannabis products is pleased to announce that it has entered into a letter of engagement with Mackie Research Capital Corporation (“Mackie”), pursuant to which Mackie, acting as sole bookrunner and lead agent, has agreed to offer for sale, together with a syndicate of agents (together with Mackie, the “Agents”), Special Warrants of the Company (the “Special Warrants”), on a commericallyy reasonable “best efforts” private placement basis, subject to all required regulatory approvals, at a price per Special Warrant of $1.05 (the “Issue Price”) for total gross proceeds of up to $5,019,000 (the “Offering”). The minimum subscriprion amount is $25,000.

Each Special Warrant shall be automatically exercisable into units of the Company (the “Units”), as described below. Each Unit shall consist of one common share of the Company (a “Share”) and one-half of one common share purchase warrant (each full warrant, a “Warrant”). Each Warrant shall entitle the holder thereof to acquire one Share at a price of $1.35 per Share for a period of 24 months following the Closing Date.

Each Special Warrant shall be automatically exercisable, for no additional consideration, into Units on the date (the “Automatic Exercise Date”) that is the earlier of: (i) the date that is three business days following the date on which the Company obtains a receipt from the applicable securities regulatory authorities (the “Securities Commissions”) for a (final) prospectus qualifying distribution of the Units underlying the Special Warrants (the “Qualifying Prospectus”), and (ii) the date that is four months and one day after the Closing of the Offering (the “Qualfication Date”).

The Company will use its commercially reasonable efforts to obtain a receipt from the Securities Commissions for the Qualifying Prospectus within 120 days of the closing of the Offering (not including the date of closing), provided, however, that there is no assurance that a Qualifying Prospectus will be filed or that a receipt therefor will be issued by the Securities Commissions prior to the expiry of the statutory four month hold period.

Notwithstanding the foregoing, in the event the Company has not received a receipt from the Securities Commissions for the Qualifying Prospectus before the date that is 30 days following the closing of the Offering (not including the date of closing), each unexercised Special Warrant will thereafter entitle the holder to receive, upon the exercise thereof, for no additional consideration, one-and-one-tenth (1.10) Unit (instead of one Unit) and thereafter at the end of each additional thirty (30) day period prior to the Qualification Date, each Special Warrant will be exercisable for an additional 0.02 of a Unit.

The Company has granted the Agents an option to offer for sale up to an additional 15% of the Special Warrants, at the Issue Price, exercisable in whole or in part at any time for a period of up to 48 hours prior to the closing date of the Offering.

The net proceeds from the Offering will be used for working capital and general corporate purposes. 

Prior to the filing of the Qualifying Prospectus and the automatic exercise of the Special Warrants, the securities issued under the Offering will be subject to a four month hold period from the date of closing of the Offering in addition to any other restrictions under applicable law.

The securities being offered have not been, nor will they be, registered under the United States Securities Act and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This news release will not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/.  

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forwardlooking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile onwww.sedar.com

 

 

** THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.**

by Ty Young

Juva Life Advances Intellectual Property Protection Program and Advises on DTC Eligibility

Juva Life Advances Intellectual Property Protection Program and Advises on DTC Eligibility

VANCOUVER, BC, — (GLOBE NEWSWIRE – January 27, 2021) – Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a California based life sciences company focused on the research and development, and commercialization of Cannabis products is pleased to offer an update regarding intellectual property protection matters and concurrent capital markets activities.

Juva Life is a life science company focused on the identification and characterization of evidenced based safe cannabis products. The Company has developed a unique platform that enables the identification of products targeting inflammatory conditions. Juva will protect these inventions through holding as trade secret certain discovery technologies and patenting novel compositions of matter and uses. Directing these activities within the Company is Sanjeev Gangwar, Ph.D., Vice President of Chemistry. Dr. Gangwar brings significant experience to this subject matter having served as a Director of Oncology Discovery Chemistry for Bristol-Myers Squibb, and a co-inventor of 45 patents.

In addition, the Company will expand its commercial trademarks. To-date, Juva has filed applications for 24 trademarks across multiple classes and goods including brand identity, brand messaging and products. The filings span multiple jurisdictions including the USA, Canada, the European Union (EUTM), and globally through the United Nations’ World Intellectual Property Organization (WIPO).

Company Founder and CEO, Doug Chloupek states, “We view the codification of our IP strategy critical to our sustainable competitive advantage which drives our commercialization and partnering plan. Our goal is to generate revenue through commercialization and to deploy revenue to discover and protect valuable and licensable products.”

In related news, the Company is pleased to announce that electronic settlements of its OTCQB-traded shares in the United States have received approval from The Depository Trust Company (“DTC”) of New York, NY and are now DTC eligible.

The Depository Trust Company (DTC) is a subsidiary of the Depository Trust & Clearing Corporation DTCC and manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible.” This electronic method of clearing securities speeds up the receipt of stock and cash, thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

“We are incredibly pleased to have secured DTC eligibility to facilitate the trading of our common shares for U.S investors and brokerage firms,” Chloupek stated. “This greatly simplifies the process of trading the Company’s common stock on the OTC marketplace in the United States allowing for faster execution and improved liquidity which will help broaden our investor base.”

In addition to the OTCQB, shares of Juva Life also continue to trade on the Canadian Securities Exchange (CSE) and Frankfurt stock exchange.

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

inquiries@juvalife.com

 

About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/. 

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”.  Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws. 

The CSE does not accept responsibility for the adequacy or accuracy of this release.

by Ty Young

Juva Life Initiates Clinical Registry as First Step in Building Evidence-Based Cannabis Technology Platform

Juva Life Initiates Clinical Registry as First Step in Building Evidence-Based Cannabis Technology Platform

VANCOUVER, BC, — (GLOBE NEWSWIRE – January 21, 2021) – Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a California-based life science company today announces the launch of a clinical registry to evaluate rationally designed cannabis formulations for clinical effect and mode of action. This is the first step towards building an integrated technology platform addressing serious and unmet medical needs.

There is a substantial body of pre-clinical, clinical, and anecdotal data consistent with a cannabis effect, but despite significant investment and opportunity, there is an absence of understanding of “how cannabis works” to pair the right formulation with the right indication. Juva has designed a novel technology platform spanning natural products pharmacology, clinical science, and digital learning. As part of this effort, Juva will employ FDA-approved metrics and best practices to validate the clinical safety and efficacy of formulations derived from our platform.

On August 25, 2020, the Juva Life-sponsored JuLi Registry was approved by the WCG IRB. Recognized as the gold standard of human research protection, the WCG Institutional Review Board is a trusted partner to more than 3,100 research institutions in the USA. The IRB has approved two locations to be used in the research and Juva’s team is working with the research facilities regarding protocols, methodologies, and recruitment of a cohort of up to 2,000 volunteer patients.

Juva Life is addressing the unmet need for small molecule anti-inflammatory consumer and pharmaceutical products initially targeting pain. A significant percentage of patients who are using cannabis are self-medicating for untreated/incompletely treated pain. This presents a substantial problem for physicians and ultimately regulatory agencies. Frequently patients resort to cannabis products when conventional drugs fail, and they exclude healthcare providers from these decisions. They correctly perceive either a lack of knowledge or belief of a cannabis effect on the part of their physicians and care providers. Juva Life is addressing this knowledge gap by developing evidence-based products that meet the needs of physicians and patients.

The current approach to cannabis research and development is largely empirical. Absent is a (new) way to quantify the clinical effect and mode of action of compounds contained within cannabis. Juva Life has developed a way to decipher and systematically evaluate the chemistry of cannabis more efficiently with less cost and reduced timelines than current practices. The Juva platform aims to develop an efficient way to standardize the development and testing of complex natural product mixtures. Central to this is a clinical registry patterned after pharmaceutical drug development best practices. By combining know how concerning mode of action, with FDA approved clinical endpoints, Juva will speed the collection of valuable evidence-based data sets to evaluate pharmacokinetic/pharmacodynamic (PK/PD) relationships, target engagement and clinical efficacy.

Juva is one of the very first companies to develop a cannabis platform to decipher the putative clinical effects of cannabis. We intend to be a world leader at the pharmacology of complex cannabis mixtures, and the development and commercialization of standardized products that meet pharmaceutical evidentiary standards. The pillars of our platform center on identification of compounds that alone or in tandem exhibit reproducible pre-clinical effects; validation in human subjects employing standard disease metrics; development of consumer and pharmaceutical products that meet the highest safety and efficacy standards; and the commercialization alone and through partnerships of products derived from our pipeline.

Vice President of Chemistry for Juva Life, Sanjeev Gangwar Ph.D. states, “Our mission is to use state of the art life science and data technologies to understand how cannabis works. There is a significant need for new solutions to serious diseases where cannabis may play a role. Our goal is to address these unmet medical needs and when coupled with our novel learning and revenue model, build a durable, important, and valuable company. The months and years ahead represent an extraordinary opportunity as we unlock that enormous potential of cannabis.”

In related news, the Company advises it has engaged the services of Creative Direct Marketing Group Inc. (CDMG) a full-service direct response advertising and digital marketing agency to increase public and investor awareness for a period of six months, for the agency fee of $2.107 million.

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder
Juva Life Inc.
inquiries@juvalife.com

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

inquiries@juvalife.com

 

 

 

About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/. 

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”.  Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

by Tom Kavanaugh

Juva Life Receives California Cultivation License for Stockton Facility

Juva Life Receives California Cultivation License for Stockton Facility

— Milestone Event to Spur Revenues and Product Development Pathway for Unmet Medical Needs

VANCOUVER, BC, — (GLOBE NEWSWIRE – January 19, 2021) – Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a premier California based multi-faceted life sciences company focused on the commercialization of Cannabis products and advanced formulations is extremely pleased to announce receipt of a state approved cannabis cultivation license for its almost 30,000 sq. ft.  facility located in Stockton, California.

After approximately 30 months of dedicated effort encompassing a comprehensive regional and municipal permitting process, extensive physical upgrades, and state of the art equipment installations, Juva has received a greenlight from CalCannabis Cultivation Licensing, a division of the California Department of Food and Agriculture (CDFA). The agency ensures public safety and environmental protection by licensing and regulating commercial cannabis cultivators statewide. CalCannabis also manages the state’s track-and-trace system, which tracks all commercial cannabis and cannabis products—from cultivation to sale.

With licensing approval, Juva is now moving swiftly to fully activate its newly upgraded facility by planting approximately 8,000 sq. ft. of flowering canopy and 5,000 sq. ft. of non-flowering canopy. An additional 4,500 sq. ft. of space has been subdivided into trim, dry storage, breeding, pre-roll, packaging, and environmental system rooms (including automated controls, water reserves, fertilization, and irrigation, etc.). Three of the five growing spaces are ready for immediate planting with another two expected to be completed by Q2, 2021. Once all five rooms are fully operational, the facility is expected to have the annual capability to produce approximately 6,000-pounds of high-quality cannabis flower. Cultivated flower production is slated for use in Juva branded products, contract production services, and clinical research targeting novel product formulations.

In addition, the facility includes almost 3,000 square feet of space for use as a delivery, packaging and distribution center. As of October 2020, Juva has operated a growing cannabis delivery fleet from this location, offering nearly 400 product SKU’s to the approximately 750,000 residents of San Joaquin County.  Plans for 2021 include expanded delivery services to the municipalities of Tracy (to the west), Modesto, (to the south) and Elk Grove (to the north).

The facility provides the residential delivery service separately from the distribution center which is designed to service B2B shipping of bulk cannabis to other licensed cannabis businesses (including related Juva facilities) as well as planned distribution of Juva branded products. The entire facility has been outfitted to be completely powered by low emission onsite natural gas generators so that electrical grid power serves as a system backup in order to reduce electrical operating costs by as much as 50%.

Company Founder and CEO, Doug Chloupek states, “This is a milestone event for Juva. Now that we can commence cultivation, we are firmly in charge of our destiny. We can control product quality and output in order to service our growing enterprise, as well as generate quantifiable returns. Our strategy integrates a path to sustainability and an ability to advance the development of novel formulations to address a myriad of unmet medical needs around the world. Todays announcement is a huge step forward and validation of our business plan to build value at every step of the process.”

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

inquiries@juvalife.com

 

About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/. 

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”.  Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws. 

The CSE does not accept responsibility for the adequacy or accuracy of this release.

by Ty Young

Juva Life Unifies and Accelerates Brand Marketing Plans

Juva Life Unifies and Accelerates Brand Marketing Plans

VANCOUVER, BC, — (GLOBE NEWSWIRE – January 14, 2021) – Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a premier California based multi-faceted life sciences company focused on the commercialization of Cannabis products and advanced formulations, is pleased to announce an upcoming strategic brand identity campaign designed to unify its messaging amongst its various products and divisions. 

Juva Life is working to unify its communication strategy and advance its brand positioning in order to more consistently represent its core mission across multiple platforms and media. The Company is embarking on an accelerated plan for growth, and as such, the need for responsible broad public awareness is increasingly paramount for the long-term success of the Company.

Company Founder and CEO, Doug Chloupek states, “Our Life Sciences efforts are instrumental for the strategic success of Juva. While our efforts to-date have laid the foundation for a solid regional cannabis enterprise, we are actively pursuing opportunities aimed at delivering a platform of products that address significant unmet medical needs. The marketing efforts required to drive awareness of our activities includes considerable forethought and planning to ensure consistent messaging to appropriately communicate the various aspects of our product development strategy. We are dedicated to laying a solid foundation for commercial success by executing a comprehensive strategic marketing plan.”

The Company has implemented a scalable approach to marketing by engaging contract vendors who meet the requisite needs for creative expertise, cost-effective methodologies, and the ability to provide a long-term perspective in a fast-paced, evolutionary environment.

As a result, Juva is incredibly pleased to be working with a growing team that includes The Idea Cooperative, a dedicated full-service creative agency of Sonoma County, California who have taken the lead role in consumer-facing brand positioning and product design. Their talents are focused on website, social media, newsletters, and other related commercial communications strategies. In addition, Juva has engaged the highly experienced, full-service design team at August Studio of Oakland, California to integrate a consistently branded look and feel throughout its brick-and-mortar facilities.

In related news, the Company has engaged investment communications, financial research, and integrated digital marketing service providers to increase public awareness regarding Juva’s activities, strategic plans, and investment opportunity. As part of Juva’s disclosure obligations as a public issuer, the terms and fees for investor relations service providers are six (6) month engagements and include Advanced Media Solutions Ltd. at $450k, Promethean Marketing Inc. at $350k, and Digitonic at $150k.

Together, these creative, communications and marketing agencies are shaping the future brand identity and public awareness of Juva Life.

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

inquiries@juvalife.com

 

About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/. 

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”.  Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws. 

The CSE does not accept responsibility for the adequacy or accuracy of this release.

by Ty Young

Juva Life Brings Bold Outlook for the New Year

Juva Life Brings Bold Outlook for the New Year

— Science, medicine, and business expertise to create evidence-based cannabis opportunity

VANCOUVER, BC, — (GLOBE NEWSWIRE – January 4, 2021) – Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a premier California based multi-faceted life sciences company focused on the commercialization of Cannabis products and advanced formulations is pleased to offer insights into activities and strategic actions for the coming year.

Company Founder and CEO, Doug Chloupek states, “As previously announced, our activities in the San Francisco Bay Area and the Central Valley are well underway with our delivery services generating growing revenues from our Redwood City and Stockton operations, and our plans are moving ahead with permitting, licensing and construction activities at our Hayward and Stockton facilities. We are just months away from increasing our revenue capability as our new facilities scale up and go online. Combined with the introduction of our advisory team in early December, we are now able to activate our proposed Life Sciences strategy for the new year.”

Juva is addressing the absence of reliable and reproducible evidence-based cannabis products that individuals can rely upon for their health needs. With the development of a proprietary technology platform to standardize and clinically validate cannabis-based products, Juva will address the need for safe evidence-based cannabis products aimed at targeting serious medical illness. In doing so, Juva will address the needs of patients/consumers, regulators, healthcare providers and commercial partners.

Juva Life’s strategy mirrors the best practices of the ethical pharmaceutical industry coupled with a modern learning strategy to develop evidence-based products faster and at a lower cost basis. This provides dual benefits to patients who desire new products to treat their needs as well as to investors who have the potential to see accelerated value creation. The cornerstone of our platform is the standardization and clinical validation of complex natural products such as cannabis.

Juva’s platform consists of the following core elements:

• IDENTIFICATION: Novel chemistry platform identifies combinations of bioactives that work together across multiple modes of action.

• VALIDATION: Evidence-based clinical development platform coupled to advanced data science tools.

• PRODUCTIZATION: Address unmet medical need spanning consumer and pharmaceutical categories.

• COMMERCIALIZATION: Vertically integrated to enable efficient unlocking of value.

“We envision a new type of cannabis company” said Chloupek. “By introducing expertise in the science of cannabis we reduce development and discovery risk, and by employing expertise in the business of cannabis we can reduce commercial risk. Through this framework we have a solid strategy to leverage our regional revenue generation through investment in peer evaluated, scientifically developed formulations that aim to offer value-multiplied licensing opportunities to a potentially global audience. If we can prove efficacy and safety with products that consumers desire, then there is a quantifiably great opportunity ahead. That’s how we aim to build a sustainable business model and grow shareholder value.”

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.
inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/.

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”.  Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

by Tom Kavanaugh

Juva Life Transforming Ex-Cancer Research Facility into Flagship Operation

Juva Life Transforming Ex-Cancer Research Facility into Flagship Operation

– Hayward Research Laboratory Positioned to Drive ‘Science of Cannabis’ Efforts

 

VANCOUVER, BC, — (GLOBE NEWSWIRE – December 22, 2020) – Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a premier California based multi-faceted life sciences company focused on the commercialization of Cannabis products and advanced formulations is pleased to provide an update regarding activities at its Hayward, California facility build-out.

Originally constructed and partially funded by federal research grants, Juva Life’s Hayward project started life as biotechnology cancer research facility focused on the development of plant-based antibodies and the study of protein expression in tobacco plants. As such, the structures on the property includes 18,000 sq. ft. of preexisting purpose-built concrete structures adjoining 11,000 sq. ft. of dedicated greenhouse canopy.

As part of the legacy infrastructure and a key feature in Juva’s future ambitions, the main building includes an ISO Class 5 cleanroom ideally suited to propel Juva’s science of cannabis strategy towards the development of advanced formulations and products. The cleanroom and adjoining laboratory spaces include plans for the installation of liquid and gas chromatography plus mass spectrometry equipment. Class 5 is considered at the more critical end of the class spectrum, requiring a greater level of filtration to achieve a level of cleanliness by typically employing Ultra Low Penetration Air (ULPA) Filtration targeting 99.9995% efficiency at 0.12 micron. This research facility is scheduled to be one of the first operational elements of the Hayward campus.

A Conditional Use Permit (CUP) was approved on October 22nd upon completion of an extremely rigorous and thorough application process. The application included many details typically included in building permit applications and, as such, it is believed may expedite additional permitting. Upon approval, immediate actions require the installation of physical perimeter security and modernized fire suppression systems. Upon installation, the Company will apply for partial occupancy to enable the outfitting of the laboratory and related processing areas in order to initiate extraction and formulation operations which are anticipated to scale to full production by mid-2021.

Upon completion of the proposed renovations, greenhouse cultivation is conditionally approved for 13,453 sq. ft. within a fully modernized facility. An internal assessment suggests that material yields of up to 4,600 pounds of total biomass inclusive of 3,600 pounds of flower could be harvested in the first full year of activity. Advanced agronomic practices within the controlled environment are anticipated to produce quantifiably premium quality and potency. The Hayward facility will ultimately total 38,000 sq. ft. in size with a manufacturing focus on advanced industrial scale extraction processes utilizing most of the internally harvested material for use in novel formulations, product development, and material supply for Juva’s related divisional activities.

Related activities planned for the Hayward campus include business to consumer (B2C) retail delivery operations offering Juva-produced and 3rd party products throughout the Eastern San Francisco Bay area. Acting as a distribution center, Juva would have the ability to ship bulk or processed product to other licensed cannabis businesses (including other current or future Juva facilities). In addition, the Company has been conditionally approved to develop a boutique flagship retail operation focused on Juva products in a designer-styled environment.  

Juva’s CEO and Founder, Doug Chloupek states, “We were extremely fortunate to discover the Hayward location early in our planning phase. The previous occupants’ operations provide us with a pre-built facility that closely matches our strategic aims and consequently expedites our ability to advance operations. I’m particularly excited that it appears our lab could be functional early to mid 2021, as the development of a broad spectrum of product formulations through applied science is a fundamental aspect of how we aim to build corporate and shareholder value.”

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

inquiries@juvalife.com

 

About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/. 

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”.  Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws. 

The CSE does not accept responsibility for the adequacy or accuracy of this release.

 

 

by Ty Young

Juva Life Features Redwood City Operational Update

Juva Life Features Redwood City Operational Update

— Cannabis delivery services position Juva for post pandemic brand loyalty and growth

 

VANCOUVER, BC, — (GLOBE NEWSWIRE – December 15, 2020) – Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a premier California based multi-faceted life sciences company focused on the commercialization of Cannabis products and advanced formulations is pleased to follow up on its November 25th news release with a featured summary of activities to-date at its Redwood City operations.

In relation to the significantly larger footprint of the Hayward and Stockton facilities which are rapidly advancing through licensing and construction phases, the Redwood City operation was designed to initially target regional delivery services and rapid territorial expansion. With a growing staff of over 14 team members and an expanding vehicle fleet which currently includes 50% hybrid electric vehicles, the service has been operational since late January of 2020.

With a functional capability to easily service the San Francisco Peninsula through its central location halfway between San Francisco and San Jose, the location serves a generally younger demographic in the Silicon Valley region. Ongoing efforts are underway to extend the delivery area to encompass adjacent high density urban centres aimed at increasing the total accessible population to an estimated 1.67 million potential customers.

Through an evolving menu of almost 400 SKU’s to choose from, including numerous award-winning and top selling products, the Juva sales team is constantly improving conversion rates and building a loyal customer base. For more information on product services, visit: www.shopjuva.com/redwood-city/.

In related news, the Company has recently obtained the option to lease a high visibility retail location on a prime corner of downtown Redwood City in a concerted bid to receive one of up to six storefront retail licenses proposed to be granted via a merit-based process by the municipality of Redwood City. Working in conjunction with the existing delivery services operational center for inventory support, the addition of storefront retail could act as a regional brand multiplier and centralized focus for enhanced consumer awareness campaigns.

Juva’s CEO and Founder, Doug Chloupek notes, “COVID-19 created some surprising opportunities and interesting challenges that our team have been able to pivot to our advantage. As a brand-new delivery service offering an extensive menu of popular items, we really had to quickly build confidence based on quality, responsiveness, merit and trust. To-date, we have successfully proven to our growing list of customers that with Juva, they can easily order the products they want, when they want, and where they want them. As news regarding vaccine rollout build hope for future, we believe we are extraordinarily well positioned to leverage our commercial activities to quickly advance marketing momentum and increase our sector positioning as, and when restrictions begin to ease. We have worked hard to get the word out during these challenging times and our efforts will definitely act as a launch pad for continued growth and greatly assist in the creation of sustainable value for our entire enterprise.”

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

inquiries@juvalife.com

 

 

 

About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/. 

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”.  Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

 

 

by Ty Young